They have pretty specific timelines - I don’t know, possibly some questions, but there is also a timeline for that.
Maybe a different pathway on Ph2 Janssen data ie CDx? My bet is on DeNovo as well, as PromarkerD has utility beyond being a companion diagnostic with Canagliflozin.
Be good to get news on FDA advice soon.
BTW what is with a “No Deal Roadshow”? I am invested in multiple biotechs and have never seen that term used before - I find it a bit bizarre the need to include that term in an ASX ANN. Why not just “Investor Presentation Roadshow”?
GLTAH
Ann: Study shows diabetes drug improves PromarkerD risk scores, page-44
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
70.5¢ |
Change
0.010(1.44%) |
Mkt cap ! $92.35M | |||
| Open | High | Low | Value | Volume |
| 71.0¢ | 71.0¢ | 69.0¢ | $10.51K | 14.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 101449 | 69.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 12.53pm 15/11/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |